Jeonbuk National University researchers reported preclinical data for an engineered Salmonella Typhimurium strain designed to target breast tumors through dual mechanisms. The platform, termed JOL3136, is attenuated using gene deletions and engineered to express apoptin and a carcinoembryonic antigen (CEA) epitope. In 4T1 mouse models, weekly dosing reduced tumor mass and volume relative to controls, with the paper describing increased CD49b-positive lymphocytes and higher interferon-gamma levels in the tumor microenvironment—signals consistent with a stimulated antitumor immune response. The study frames the approach around safer bacterial delivery and improved tumor localization through tumor-dependent tryptophan limitation, reinforcing interest in microbiome-adjacent and live-vector cancer strategies while remaining at the preclinical stage.
Get the Daily Brief